Case Report
The Journal of the Korean Rheumatism Association 2006; 13(3): 230-235
Published online September 30, 2006
© Korean College of Rheumatology
중증 전신홍반루푸스에서 Rituximab의 사용 경험 2예
황기원·안용성·문지윤·김일영·박영은·김근태*·이준희·김성일
부산대학교 의과대학 내과학교실, 부산의료원 내과*
Experience of Rituximab Treatment in Two Patients with Severe Systemic Lupus Erythematosus
Correspondence to : Sung Il Kim
Rituximab is a chimeric monoclonal antibody for human B lymphocyte subset CD20 and has recently been used for treatment of autoimmune disease such as rheumatoid arthritis and systemic lupus erythematosus (SLE). We report the experiences of rituximab treatment in two patients with severe SLE. The first case is 16-year-old female patient with hemolytic anemia, thrombocytopenia and acute renal failure due to aggravation of lupus nephritis, and the second case is 30-year-old female pregnant patient with diffuse alveolar hemorrhage after preterm premature rupture of fetal membranes. All two patients responded to rituximab and maintained symptom free state.
Keywords Rituximab, Systemic lupus erythematosus
PDF
Standard view
Export citation
Share Article
Case Report
The Journal of the Korean Rheumatism Association 2006; 13(3): 230-235
Published online September 30, 2006
Copyright © Korean College of Rheumatology.
중증 전신홍반루푸스에서 Rituximab의 사용 경험 2예
황기원·안용성·문지윤·김일영·박영은·김근태*·이준희·김성일
부산대학교 의과대학 내과학교실, 부산의료원 내과*
Experience of Rituximab Treatment in Two Patients with Severe Systemic Lupus Erythematosus
Ki Won Hwang, M.D., Yong Sung Ahn, M.D., Ji Yoon Moon, M.D., Il Young Kim, M.D., Young Eun Park, M.D., Geun Tae Kim, M.D.*, Jun Hee Lee, M.D., Sung Il Kim, M.D.
Department of Internal Medicine, Pusan National University College of Medicine, Department of Internal Medicine, Pusan Medical Center*, Busan, Korea
Correspondence to:Sung Il Kim
Abstract
Rituximab is a chimeric monoclonal antibody for human B lymphocyte subset CD20 and has recently been used for treatment of autoimmune disease such as rheumatoid arthritis and systemic lupus erythematosus (SLE). We report the experiences of rituximab treatment in two patients with severe SLE. The first case is 16-year-old female patient with hemolytic anemia, thrombocytopenia and acute renal failure due to aggravation of lupus nephritis, and the second case is 30-year-old female pregnant patient with diffuse alveolar hemorrhage after preterm premature rupture of fetal membranes. All two patients responded to rituximab and maintained symptom free state.
Keywords: Rituximab, Systemic lupus erythematosus
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea
Su Jin Choi, M.D., Soo Min Ahn, M.D., Ji Seon Oh, M.D., Ph.D., Seokchan Hong, M.D., Ph.D., Chang-Keun Lee, M.D., Ph.D., Bin Yoo, M.D., Ph.D., Yong-Gil Kim, M.D., Ph.D.
J Rheum Dis 2022; 29(1): 22-32 -
Catastrophic Antiphospholipid Syndrome Associated with Systemic Lupus Erythematosus Successfully Treated with Rituximab: A Case Report
JinShik Shin, Kwang Nam Kim
J Rheum Dis 2019; 26(1): 74-78 -
A Case of Rituximab Therapy in Diffuse Alveolar Hemorrhage of Systemic Lupus Erythematosus Refractory to Steroid Pulse Therapy
Sang Woo Yim, Chang Kyoo Byon, Jun Yong Park, Sang Yeob Lee, Sung Won Lee, Won Tae Chung
J Rheum Dis 2014; 21(4): 201-204
